and a hands-on examiner. 6, 7 However, the remote specialist's score in those prior studies depended on an in-home examiner who provided positioning, instructions to patient, and assistance with components of the examination that require direct contact. 6, 7 The third reported the multimodal remote EDSS evaluation and a video of a self-performed neurological examination (patients previously trained) along with patient-reported questionnaires and other tools. 8 To develop a tele-EDSS evaluation optimized for care and research in patients with MS that does not require the presence of an in-home hands-on examiner and that is valid in patients with lower disability scores (less weighted toward ambulation), we generated a modified "tele-EDSS" examination using a low-cost, secure, and compliant telemedicine tool as well as a basic "neurokit," and tested it against an EDSS assessment performed by a trained and certified neurologist. Importantly, the examination did not rely on an in-home aide unless the patient had required assistance for travel to their clinic visit. Secondarily, we identified which portions of the standardized in-clinic EDSS were least amenable to a telemedicine-based evaluation.
Materials and methods

Participants
Adult participants (ages: 18-75 years) were recruited from the University of California, San Francisco (UCSF) MS and Neuroinflammation Center, a large academic MS clinic in California, USA. Participants with a diagnosis of clinically isolated syndrome (CIS) or MS by 2010 International Panel (Revised McDonald) criteria 9 were eligible to participate if they had access to a home device (computer, laptop, tablet, or smartphone) that was Internet-enabled (cable or wifi) and were willing to undergo a home evaluation within 72 h of their clinical evaluation.
In-clinic recruitment (August-September 2016).
Patients with CIS/MS were approached after their scheduled clinic appointments with one of four neurologists specialized in MS and certified in the Neurostatus EDSS examination 10 (C.J.B., R.B., EC, J.M.G.). Participants were consecutively approached on convenience days (study coordinator in clinic) and invited to undergo a second, telemedicine-based, evaluation within 72 h. Of the 30 patients approached, 23 met all study criteria and were enrolled.
Cohort-based recruitment (March-August 2017).
Patients with CIS/MS who underwent an annual standardized EDSS as part of their involvement in the UCSF EPIC (Expression, Proteomics, Imaging, Clinical) longitudinal study (http://msepicstudy.com) 11 performed by a single examiner (C.J.B.) as part of their annual EPIC neurological evaluations, were recruited to undergo a tele-EDSS examination performed by one of two examiners (R.B., J.M.G.) within 1 week. Of 26 patients approached, 21 met all study criteria and were enrolled.
Procedures
In-person EDSS. A Neurostatus-based standardized EDSS evaluation was performed during the clinical or study visit.
Telemedicine-enabled EDSS. Participants were then scheduled to undergo a televideo-enabled visit within 72 h from a private location of their choice (e.g. home and office). Participants received instructions on downloading and accessing the telemedicine software onto their camera-enabled smartphone, tablet, or laptop/desktop. If participants did not meet the technology requirements to carry out the televideo visit, they also received a webcam, free of cost, along with a shipping label to return at the conclusion of the study (N = 3). Participants then received an "inhome neuro kit" (Rosenbaum 14-inch vision card, US$5; 128 Hz tuning fork, US$9; safety pin, long cotton swab, and alcohol swab <US$1 combined; tax and shipping = US$5; total cost per bag <US$20). In order to mimic a research scenario where a kit might be mailed to prospective study participants, participants did not receive instructions in use of these tools prior to the telemedicine encounter; however, subjects did receive instructions in use of the tools and in positioning of the camera real-time. Additional details of the tele-EDSS script and logistics are provided in the Supplementary Material. Briefly, the tele-EDSS was modified from the EDSS, performed over a secure video chat, where the examiner uses verbal instructions because they cannot directly examine the patient. A prior version of a tele-EDSS was tested at other centers 6,7 and the current version was refined by R.B., C.B., EC, J.M.G., and M.T.W. to allow for more instructions to the patient, given the absence of an in-home examiner. In each case, a clinician who had never evaluated the patient performed the examination. To reduce potential learning effects from patients learning the examination components, patients were informed that examinations can often vary from day to day and were instructed not to offer any information from their previous in-person evaluation. An aide was allowed in the room with the patient if the patient required someone to accompany them to the in-person visit. 
Ethical approvals
The UCSF Institutional Review Board approved the protocol, and written informed consent was obtained from all participants.
Statistical analyses. Descriptive statistics were used to evaluate demographic, disease, and televideo visit characteristics. Kappa statistics compared the in-person and in-home EDSS examinations. In sensitivity analyses, age, sex, and education were adjusted for, and functional impairments were stratified (EDSS range, ambulation, cognition, and vision). We replicated a previously reported analysis of patientreported EDSS scores to further evaluate the utility of these scores. 12 Data were analyzed using the SAS software program JMP, version 8.0.1 (Cary, NC).
Results
Clinical and demographic characteristics
Feasibility. The majority of patients approached were interested in the study. Of 56 participants approached, 44 were interested, met all study criteria and enrolled; 41 completed the in-clinic and telemedicine-based evaluations. Reasons for non-participation or completion included lack of time, family emergencies, and work-related travel. The 41 participants who completed both evaluations did not differ in sex, age, disease duration, EDSS, or disease-modifying treatment (DMT) category from participants with missing or partial evaluations. While the initial goal was to complete all visits within 72 h of the inclinic evaluation, this timeframe was expanded to 7 days due to the need to accommodate weekends, travel time back home from the Center, and other factors. The median delay between in-clinic and telemedicine evaluations was 2 days. No participant experienced a clinical relapse during the 7-day interval between assessments, as determined by the clinician performing the telemedicine-based evaluation.
Clinical and demographic features. Demonstrating that interest in telemedicine is not limited to younger populations, the mean age was 47 years (range: 23-73; interquartile range (IQR): 38-53), with 19 individuals (46%) aged 50 or above (Table 1) . A broad range of disability (0-7) was captured, with a median EDSS of 2.
Telemedicine evaluations. Most participants' visits (N = 30, 73%) were performed on a smartphone; others were performed on a tablet (N = 6), laptop (N = 3), or desktop (N = 2). All examiners' visits were performed using a laptop or desktop.
For clinical evaluations, 32 participants (78%) presented alone; the others were accompanied by a partner or spouse (N = 5), friend (N = 2), or parent or other family member (N = 2). For telemedicine evaluations, 37 participants (90%) were evaluated without any other person in the room; this included the 32 participants who came to the clinic unaccompanied, as well as five of the nine participants who had been accompanied to the clinical visit. No participants who came to clinic unaccompanied required an aide on telemedicine. Four participants elected to have an aide during the remote encounter.
Comparison of in-clinic and telemedicine-based EDSS scores
The median (IQR) for the in-clinic EDSS was 2 (1.5-4) and for the tele-EDSS was 2.5 (2-4.5). As Pearson's correlations between in-clinic and tele-EDSS scores obtained in the clinic-based (r = 0.876) and cohortbased (r = 0.898) participants were very similar, the data were pooled and analyzed together. Overall, Pearson's correlation between in-clinic and telemedicine-based EDSS scores was 0.887 (p < 0.0001).
These EDSS scores were evaluated in detail based on a previously published rationale for deployment of patient-reported EDSS scores. 12 
Clinical scenario 1 Using tele-EDSS interchangeably with EDSS:
agreement. Overall, mean difference between the scores (tele-EDSS-EDSS) was 0.34 (range: -1 to 2.5, standard deviation (SD): 0.84, 95% confidence interval (CI): 0.07-0.61, difference between the 95% CIs of 0.54; Table 2 ). This mean difference was driven by higher tele-EDSS scores at the lower EDSS ranges of 0-3.5 (mean = 0.50, 95% CI: 0.19-0.82) and driven by slightly higher EDSS scores at higher EDSS range of 4-5.5 (mean = -0.08, (95% CI: -1.20 to 1.04)) and EDSS 6-7 (mean = -0.10, (95% CI: -0.38 to 0.18)). This difference was more positive at lower EDSS scores, and more negative at higher scores (as was also reported for patient-reported EDSS 12 as well as tele-EDSS 13 evaluations).
We then deployed three measures of agreement as previously outlined. 12 We first deployed the BlandAltman plot (Figure 1 ), which would help determine whether tele-EDSS could be used interchangeably with the in-person EDSS. The Bland-Altman plot visualizes agreement by contrasting the difference between the two scores against the reference score (in-person EDSS). The mean difference between tele-EDSS and in-person EDSS was plotted as a horizontal line, as well as the 95% limits of agreement (mean Table 2 , the overall mean difference between the 95% limits of agreement was 3.3. This difference was 3.4 in patients with an EDSS score of 5.5 of lower (in whom EDSS change considered to be clinically significant is 1). 14 In contrast, it was 0.88 in patients with an EDSS of 6 or above, where EDSS change considered to be clinically significant is 0.5. 14 In our two additional measures of agreement, the unweighted kappa statistic (i.e. the proportion of agreement in excess of that expected by chance) for agreement within 0.5 points was 0.72 (Table 3) , and the intra-class coefficient (IC; that is, the proportion of total variance due to the differences between patients, while the rest is attributed to differences between tele-EDSS and in-person EDSS) was 0.89 (Table 3) .
Putting tele-EDSS-EDSS agreement in the context of inter-rater EDSS agreement.
Overall agreement appeared similar, although slightly inferior, between EDSS and tele-EDSS in this study. Previously reported inter-rater agreement (same seniority of raters) of in-clinic EDSS evaluations across a wide EDSS range are displayed in Table 3 . 12, [15] [16] [17] [18] [19] The contribution of individual FS scores to tele-EDSS-EDSS agreement. Next, to explore the relative contribution of FS scores to the tele-EDSS-EDSS difference, we performed an analysis of covariance (ANCOVA) with EDSS and FS differences as covariates, and the tele-EDSS-EDSS difference as the dependent variable, as previously described. 12 The pyramidal, cerebellar, sensory, and bowel/bladder score differences significantly affected the variance in tele-EDSS-EDSS difference, indicating that the differences between physicians and patients in the scoring of these domains were contributing to the overall difference in scoring between the tele-EDSS and EDSS. The beta coefficient describes how much the (tele-EDSS-EDSS) difference changed when the FS difference increased by 1 point. Stepwise multivariate linear regression of the EDSS and functional score differences against the tele-EDSS-EDSS difference identified the pyramidal and sensory domains as the FS in which differences between in-clinic and tele scores significantly affected the total tele-EDSS-EDSS difference (standardized beta coefficients for pyramidal = -0.437; and for sensory = 0.413).
Clinical scenario 2 Using tele-EDSS on its own: correlation.
To determine whether tele-EDSS could be used throughout a study to substitute for EDSS (without comparison with an EDSS in the data set), we evaluated the correlation between tele-EDSS and EDSS. The tele-EDSS correlated very highly with the EDSS overall ( Table 4) . Correlation for individual FS ranged from modest (0.366 for vision) to high (0.789 for bowel/ bladder). In all FS, there was >80% agreement within 1 point.
Conclusion
In this proof of principle study, we demonstrated high acceptance for participation in tele-EDSS examinations and that good correlations with in-clinic EDSS assessments can be obtained through teleneurology by an examining neurologist. This evaluation can be optimized for deployment in settings where distance or disability separates patients from specialty MS care for a relatively low cost. Furthermore, this was achieved at a range of ages and ambulatory EDSS scores (i.e. that rely more on FS other than ambulation). These findings support further development of a tele-EDSS for both clinical and research purposes with the goals of even greater reproducibility and ease for participants and examiners.
Telemedicine holds great promise for reducing barriers of access to specialized neuroscientific care and research. The proof-of-concept Brighten Trial demonstrated that the use of telemedicine for remote recruitment, enrollment, treatment, and evaluation of patients with depression is feasible. 20 A home-based trial in pediatric migraine also demonstrated the feasibility of remote telemedicine assessments as an alternative to in-person trial visits. 1 A reliable tele-EDSS examination could allow MS specialists to remotely evaluate patients who are fairly stable clinically, while sparing patients the financial and opportunity costs, caregiver burden, and traveling to their clinical appointments. With further refinement and validation, a tele-EDSS has the potential to be used for screening and for some clinical and clinical research assessments. We previously showed that patients with MS successfully engaged in patient-powered platforms 2 and participate in smartphone-based 3 or wearablebased 4 research assessment without any major evidence for a "digital divide" (i.e. basis toward more technology-savvy, younger populations) in individuals in the ambulatory range (EDSS: 0-7). Where applicable, a number of other obstacles, such as collection and storage of blood or other specimens for future analyses, or collection of magnetic resonance images (MRIs) across harmonized imaging protocols, must also be overcome for full deployment of remote trials in MS.
Our study confirms the feasibility of tele-EDSS evaluations. These were previously reported in two smaller (N = 20) studies developed by the highly innovative Veterans Affairs Home Automated Telemanagement system for patients with MS. 6, 7 The first of these studies compared scores on the Neurostatus EDSS by a hands-on experienced midlevel practitioner and the score provided by a remote neurologist specialized in MS, who was directing the mid-level practitioner's examination over a pan/tilt/ zoom camera. The correlation for the hands-on examiner versus remote specialist was 0.97 for the EDSS score. Both ratings were based on one hands-on examiner performing the evaluation; all examiners had access to the same in-person measured walk and visual acuity scores and the mean Neurostatus EDSS score in these patients was 6 (SD: 1.5, a range of disability primarily influenced by ambulatory function). 6, 7 In the second study, 20 patients with MS were examined in turn (single visit, cross-over design) by one in-person clinician and one remote clinician who used a low-cost webcam and instructed a research assistant without medical training in the home for positioning, instructions, and assistance with components of the examination that require direct contact. There were no significant (i.e. p < 0.05 on Fisher's exact test) differences reported for the EDSS or any Kurtzke subcategories of the FS scores (demographic and disease characteristics, including EDSS range, Interestingly, the agreement in this project seemed only modestly inferior to that reported for inter-rater agreement between two similarly trained clinicians both performing in-person evaluations. The agreement tended to improve with higher EDSS scores; a result that would be predicted given higher the known variability in EDSS scores in mild to moderately disabled patients and the greater dependence on ambulation of higher EDSS scores, which is more readily measured. However, the Bland-Altman plots suggest that tele-EDSS cannot be used interchangeably with the physician-derived EDSS, which is consistent with findings reported for patient-reported EDSS scales as well. 12 Rather, a more useful application of tele-EDSS could be for periodic assessment of patients known from an in-clinic evaluation to a specific examiner, or for sole use in monitoring of a remote research cohort.
Limitations of this study included the fact that the number of participating clinicians (4) and of different clinicians for the two conditions (tele-EDSS and in-clinic EDSS) likely introduced added sources of variability, as it was not possible to entirely distinguish differences in the conditions from expected inter-rater variability; however, the use of the same rater for both evaluations would have biased evaluations and use of various examiners is typical of real-world clinical care. The fact that all participants were examined after their inperson evaluation, where they might have been made more aware of, and hence pay attention to, specific deficits (e.g. sensory) that might exclude the applicability of the current findings to participants unaccustomed to neurological evaluations. Reassuringly, there were minimal differences in agreement between participants recruited from a long-term observational UCSF cohort (EPIC study 10 participants undergo annual EDSS examinations) and from the clinic (evaluations may be more variably performed). It was also not possible to exclude the role of daily fluctuations in function in leading to EDSS differences, given that the evaluations occurred on different days. Finally, this study also included primarily subjects with relapsing forms of MS. Although it is reassuring that agreement increased substantially above EDSS levels of 4, further research and validation will be needed in progressive forms of MS.
In the next steps, an iterative methodology will allow us to sequentially leverage new tools and technologies (e.g. vibration test) for precision across multiple MS-related functional domains, and for testing in specific clinical use cases (e.g. home-based evaluation to distinguish relapse from pseudo-relapse related to infection or metabolic disturbance). Specifically, for research, it would be possible to screen, enroll, and monitor participants in remote trials in whom clinical disability represents an important baseline covariate rather than a primary trial outcome. For example, in clinical trials whose primary goal is to assess improvement in specific symptoms such as cognition, fatigue, or bladder dysfunction using patient-reported or wearable measures, tele-EDSS scores could provide clinically relevant context without the added burden of in-clinic assessments.
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